Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000160891 | SCV000211583 | uncertain significance | not provided | 2014-08-26 | criteria provided, single submitter | clinical testing | This variant is denoted PMS2 c.199G>A at the cDNA level, p.Glu67Lys (E67K) at the protein level, and results in the change of a Glutamic Acid to a Lysine (GAA>AAA). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. PMS2 Glu67Lys was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Since Glutamic Acid and Lysine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. PMS2 Glu67Lys occurs at a position that is well conserved across species and is located in ATPase domain (Fukui 2011). In silico analyses predict that this variant is probably damaging to protein structure and function. Based on currently available information, it is unclear whether PMS2 Glu67Lys is pathogenic or benign. We consider it to be a variant of uncertain significance. |